Activity of Delafloxacin and Levofloxacin against Stenotrophomonas maltophilia at Simulated Plasma and Intrapulmonary pH Values
Authors:
Open Access
- 31 August 2022
- journal article
- research article
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (4) , e0270521
Abstract
Stenotrophomonas maltophilia most often infects the lungs, where the physiologic environment is naturally slightly acidic (pH ~6.6), compared to most parts of the body (such as the bloodstream), which have neutral pH values (~7.4). Pneumonia due to S. maltophilia is often treated with the antibiotic levofloxacin, despite the activity of levofloxacin being known to be impaired at acidic pH.Keywords
This publication has 40 references indexed in Scilit:
- Stenotrophomonas maltophilia: an Emerging Global Opportunistic PathogenClinical Microbiology Reviews, 2012
- Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin againstStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2011
- Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic reviewJournal of Antimicrobial Chemotherapy, 2008
- Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 MacrophagesAntimicrobial Agents and Chemotherapy, 2006
- Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophiliaDiagnostic Microbiology and Infectious Disease, 2005
- Innate Host Defense of the Lung: Effects of Lung-lining Fluid pHLung, 2004
- Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic modelInternational Journal of Antimicrobial Agents, 2004
- Activities of Ciprofloxacin and Moxifloxacin against Stenotrophomonas maltophilia and Emergence of Resistant Mutants in an In Vitro Pharmacokinetic-Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2004
- Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance ProgrammeJournal of Antimicrobial Chemotherapy, 2003
- In Vitro Antibacterial Potency and Spectrum of ABT-492, a New FluoroquinoloneAntimicrobial Agents and Chemotherapy, 2003